Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Pharmacists (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 24, 2008
A Pill For Every Mouth
Analysis of: Are Costly Diabetes Pills Doing Any Good? | www.pharmalot.com
Author: GLG Expert Contributor
Our obsession with quick fixes and a lack of focus on lifestyle changes will provide sub-optimal results.  Without comparative effectiveness trials, there is no way to gauge the value of these new therapies.
November 24, 2008
Off Label Use Can Be Prevented
Analysis of: Use of Antipsychotics in Children Is Criticized | www.nytimes.com
Author: GLG Expert Contributor
Current PBM adjudication technology can stop a prescription from being a covered benefit when an atypical is being prescribed in the pediatric setting.  the  dispensing pharmacist would receive a prior authorization required message and a discussion with the prescribing MD would be required. ...
November 24, 2008
This strategy is running out of steam.
Analysis of: How a Drug Maker Tries to Outwit Generics | online.wsj.com
Author: GLG Expert Contributor
These strategies are running out of steam as insurers, and even the general public, are catching on.  Most insurers will only pay for generic modafanil, and these new versions will not sell as much as they would have even 5 years ago.  The abuse potential of the drug may help, as brand-name...
November 13, 2008
Who can tolerate these doses and for how long?
Analysis of: CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study | www.astrazeneca.com
Author: GLG Expert Contributor
20 mg of Crestor is a high dose associated in many studies with a higher incidence of side effects.  Since compliance is historically poor with any maintenance medication, it will be interesting to see if patients with normal LDL with stay compliant with this statin or any statin in the higher...
November 13, 2008
Tamper Proof Narcotic Pain pill? YES
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: David Zimmerman, President/Owner, Doctors of Pharmacy, Inc.
This drug will allow patients in severe pain to get the necessary pain relief and not have to worry about the other patients that abuse the drug.
November 12, 2008
Science vs Marketing
Analysis of: Pharma need not worry too much about President Obama | www.pharmatimes.com
Author: GLG Expert Contributor
The Obama vision is based on science driving the prescription process.  As such, DTC advertising and the sampling of brand name medications will either be restricted or incentives provided to MDs to replace samples with vouchers.  PBMs will be required to be absolutely transparent and Medicare...
October 16, 2008
Does this dosage form really add anything?
Analysis of: Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference | www.pipelinereview.com
Author: GLG Expert Contributor
The comparator product to oxybutynin topical gel (OTG) is Ditropan XL which is also a once daily drug.
October 13, 2008
This is not a study!
Analysis of: St John's Wort 'as good as Prozac' | ukpress.google.com
Author: GLG Expert Contributor
The word "study" should not have appeared in the first sentence of the article.  What we have here is commonly known as a "meta-analysis".  A meta-analysis is nothing more than a simple tool that obviates the need to pull multiple studies to make one point or another. ...
September 15, 2008
Velcade has multiple efficcay
Analysis of: Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
Author: GLG Expert Contributor
It is very good news atht Velcade approved for previously untreated multiple Myeloma. Velcade has multiple efficacy as treatmnet is concerned for other diseases too ( Diabetes-II, Cardiovascular disease) as the mechanism of action is same for those target ( proteasome  inhibitors).
September 11, 2008
Onglyza (saxagliptin) has a great scope for Diabetes-II
Analysis of: BMS, AstraZeneca present saxagliptin data | www.fiercebiotech.com
Author: GLG Expert Contributor
Saxagliptin has good positive resluts in Phase-III trial.Still noe there i snor side effect reported. Thsi drug will compete  with Januvia ( merck). But Saxagliptin is better situtaion as the mechanism of action is concerned on DPP-4.

Page : 1 2 3 4 5 6 7 8 Next1 to 10 of 80

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203